Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

P450 inhibitor ketoconazole increased the intratumor drug levels and antitumor activity of fenretinide in human neuroblastoma xenograft models.

Lopez-Barcons L, Maurer BJ, Kang MH, Reynolds CP.

Int J Cancer. 2017 Jul 15;141(2):405-413. doi: 10.1002/ijc.30706. Epub 2017 May 9.

2.

Application of recombinant and non-recombinant peptides in the determination of tumor response to cancer therapy.

Lopez-Barcons LA, Ali AN, Diaz R.

Curr Pharm Biotechnol. 2011 Feb 1;12(2):320-35. Review.

PMID:
21050162
3.

Pegylated arginase I: a potential therapeutic approach in T-ALL.

Hernandez CP, Morrow K, Lopez-Barcons LA, Zabaleta J, Sierra R, Velasco C, Cole J, Rodriguez PC.

Blood. 2010 Jun 24;115(25):5214-21. doi: 10.1182/blood-2009-12-258822. Epub 2010 Apr 20.

4.

Human prostate cancer heterotransplants: a review on this experimental model.

Lopez-Barcons LA.

Asian J Androl. 2010 Jul;12(4):509-18. doi: 10.1038/aja.2010.17. Epub 2010 Apr 5. Review.

5.

Small-cell neuroendocrine carcinoma of the prostate: are heterotransplants a better experimental model?

Lopez-Barcons LA.

Asian J Androl. 2010 May;12(3):308-14. doi: 10.1038/aja.2009.68. Epub 2009 Dec 21. Review.

6.

Human benign prostatic hyperplasia heterotransplants as an experimental model.

Lopez-Barcons LA.

Asian J Androl. 2010 Mar;12(2):157-63. doi: 10.1038/aja.2009.77. Epub 2009 Nov 30. Review.

7.

Serially heterotransplanted human prostate tumours as an experimental model.

Lopez-Barcons LA.

J Cell Mol Med. 2010 Jun;14(6B):1385-95. doi: 10.1111/j.1582-4934.2009.00957.x. Epub 2009 Oct 29. Review.

8.

Targeting protein translation in human non small cell lung cancer via combined MEK and mammalian target of rapamycin suppression.

Legrier ME, Yang CP, Yan HG, Lopez-Barcons L, Keller SM, Pérez-Soler R, Horwitz SB, McDaid HM.

Cancer Res. 2007 Dec 1;67(23):11300-8.

9.

Potentiation of taxol efficacy and by discodermolide in ovarian carcinoma xenograft-bearing mice.

Huang GS, Lopez-Barcons L, Freeze BS, Smith AB 3rd, Goldberg GL, Horwitz SB, McDaid HM.

Clin Cancer Res. 2006 Jan 1;12(1):298-304.

10.
11.

Enhancement of the therapeutic efficacy of taxol by the mitogen-activated protein kinase kinase inhibitor CI-1040 in nude mice bearing human heterotransplants.

McDaid HM, Lopez-Barcons L, Grossman A, Lia M, Keller S, Pérez-Soler R, Horwitz SB.

Cancer Res. 2005 Apr 1;65(7):2854-60.

12.

The novel highly lipophilic topoisomerase I inhibitor DB67 is effective in the treatment of liver metastases of murine CT-26 colon carcinoma.

Lopez-Barcons LA, Zhang J, Siriwitayawan G, Burke TG, Perez-Soler R.

Neoplasia. 2004 Sep-Oct;6(5):457-67.

13.

Exogenous expression of H-cadherin in CHO cells regulates contact inhibition of cell growth by inducing p21 expression.

Zhong Y, Lopez-Barcons L, Haigentz M Jr, Ling YH, Perez-Soler R.

Int J Oncol. 2004 Jun;24(6):1573-9.

PMID:
15138602
14.

Pentapeptide YIGSR-mediated HT-1080 fibrosarcoma cells targeting of adriamycin encapsulated in sterically stabilized liposomes.

Lopez-Barcons LA, Polo D, Reig F, Fabra A.

J Biomed Mater Res A. 2004 Apr 1;69(1):155-63.

PMID:
14999763
15.

Complex effects of Ras proto-oncogenes in tumorigenesis.

Diaz R, Lopez-Barcons L, Ahn D, Garcia-Espana A, Yoon A, Matthews J, Mangues R, Perez-Soler R, Pellicer A.

Carcinogenesis. 2004 Apr;25(4):535-9. Epub 2003 Nov 21.

PMID:
14633661
16.

The N-ras proto-oncogene can suppress the malignant phenotype in the presence or absence of its oncogene.

Diaz R, Ahn D, Lopez-Barcons L, Malumbres M, Perez de Castro I, Lue J, Ferrer-Miralles N, Mangues R, Tsong J, Garcia R, Perez-Soler R, Pellicer A.

Cancer Res. 2002 Aug 1;62(15):4514-8.

17.

Down-regulation of E-cadherin in mouse skin carcinoma cells enhances a migratory and invasive phenotype linked to matrix metalloproteinase-9 gelatinase expression.

Llorens A, Rodrigo I, López-Barcons L, Gonzalez-Garrigues M, Lozano E, Vinyals A, Quintanilla M, Cano A, Fabra A.

Lab Invest. 1998 Sep;78(9):1131-42.

PMID:
9759657
18.

Metastatic ability of MXT mouse mammary subpopulations correlates with clonal expression and/or membrane-association of gelatinase A.

Llorens A, Vinyals A, Alia P, López-Barcons L, Gonzalez-Garrigues M, Fabra A.

Mol Carcinog. 1997 May;19(1):54-66.

PMID:
9180929
19.

Suppression of the metastatic phenotype of a mouse skin carcinoma cell line independent of E-cadherin expression and correlated with reduced Ha-ras oncogene products.

Caulín C, López-Barcons L, Gonzáles-Garrigues M, Navarro P, Lozano E, Rodrigo I, Gamallo C, Cano A, Fabra A, Quintanilla M.

Mol Carcinog. 1996 Feb;15(2):104-14.

PMID:
8599577

Supplemental Content

Loading ...
Support Center